Obtaining positive clinical outcomes in solid tumors like CRC and PDAC has been more challenging due to (1) heterogeneous expression of candidate surface antigens, (2) a more complicated homing to the tumor site, and (3) immune suppression by the hostile TME, including strong stromal barriers consisting of high amounts of CAFs [21, 43]. This evidence concerns the gene TBX1 and neoplasm.